Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer

Radiation Oncology

Raymond Meyn⁴  Paul Mathew²  Deborah Kuban³  Kathy Mason⁴  Kathleen Bridges⁴  Tommy Sheu⁴  Colin Brooks¹ 

[1] National University of Galway (NUIGalway), Galway, Ireland;Department of Hematology-Oncology, Tufts Medical Center, Boston, MA, USA;Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA;Department of Experimental Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

关键词: Radiation;    Tyrosine kinase inhibitor;    Prostate cancer;    Targeted therapy;    Combinational therapy;    Sunitinib;   

Others  :  1155315
DOI  :  10.1186/1748-717X-7-154

 received in 2012-05-24, accepted in 2012-08-25,  发布年份 2012

【 摘 要 】

Background

Many prostate cancers demonstrate an increased expression of growth factor receptors such as vascular endothelial growth factor receptor (VEGFR) and platelet derived growth factor receptor (PDGFR) which have been correlated with increased resistance to radiotherapy and poor prognosis in other tumors. Therefore, response to radiation could potentially be improved by using inhibitors of these abnormally activated pathways. We have investigated the radiosensitizing effects of sunitinib, a potent, multi-tyrosine kinase inhibitor of the VEGFR and PDGFR receptors, on human prostate cancer cells.

Methods

The radiosensitizing effects of sunitinib were assessed on human prostate cancer cell lines DU145, PC3 and LNCaP by clonogenic assay. Sunitinib’s ability to inhibit the activities of its key targets was determined by immunoblot analysis. The radiosensitizing effects of sunitinib in vivo were tested on human tumor xenografts growing in nude mice where response was assessed by tumor growth delay.

Results

Clonogenic survival curve assays for both DU145 and PC3 cells showed that the surviving fraction at 2 Gy was reduced from 0.70 and 0.52 in controls to 0.44 and 0.38, respectively, by a 24 hr pretreatment with 100 nM sunitinib. LNCaP cells were not radiosensitized by sunitinib. Dose dependent decreases in VEGFR and PDGFR activation were also observed following sunitinib in both DU145 and PC3 cells. We assessed the ability of sunitinib to radiosensitize PC3 xenograft tumors growing in the hind limb of nude mice. Sunitinib given concurrently with radiation did not prolong tumor growth delay. However, when animals were treated with sunitinib commencing the day after fractionated radiation was complete, tumor growth delay was enhanced compared to radiation alone.

Conclusions

We conclude, based on the in vivo results, that sunitinib and radiation do not interact directly to radiosensitize the PC3 tumor cells in vivo as they did in vitro. The fact that tumor growth delay was enhanced when sunitinib was given after radiotherapy was completed suggests that sunitinib may be acting on the irradiated tumor stroma and suppressing its ability to sustain regrowth of the irradiated tumor. Based on these preclinical findings, we suggest that the combination of sunitinib and radiation for the treatment of prostate cancer deserves further development.

【 授权许可】

   
2012 Brooks et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 2.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Pisansky TM: External beam radiotherapy as curative treatment of prostate cancer. Mayo Clin Proc 2005, 80(7):883-898.
• [2]Kim DW, Huamani J, Fu A, Hallahan DE: Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy. Init J Radiation Oncology Biol Phys 2006, 64(1):38-46.
• [3]Abdollahi A, Lipson KE, Han X, Krempien R, Trinh T, Weber KJ, Hahnfeldt P, Hlatky L, Debus J, Howlett AR, et al.: SU5416 and SU6668 Attenuate the Angiogenic Effects of Radiation-induced Tumor Cell Growth Factor Production and Amplify the Direct Anti-endothelial Action of Radiation in Vitro. Cancer Res 2003, 63(13):3755-3763.
• [4]Wachsberger P, Burd R, Dicker AP: Tumor Response to Ionizing Radiation Combined with Antiangiogenesis or Vascular Targeting Agents: Exploring Mechanisms of Interactions. Clin Cancer Res 2003, 9(6):1957-1971.
• [5]Motzer RJ, Hoosen S, Bello CL, Christensen JG: Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin Investig Drugs 2006, 15(5):553-561.
• [6]Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, et al.: In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors. Clin Cancer Res 2003, 9(1):327-337.
• [7]de Boüard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, Guillamo J-S: Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol 2007, 9(4):412-423.
• [8]Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM: SU11248 Inhibits KIT and Platelet-derived Growth Factor Receptor β in Preclinical Models of Human Small Cell Lung Cancer. Mol Cancer Ther 2003, 2(5):471-478.
• [9]Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM, Mendel DB: Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther 2006, 5(5):1280-1289.
• [10]Cuneo KC, Geng L, Fu A, Orton D, Hallahan DE, Chakravarthy AB: SU11248 (Sunitinib) Sensitizes Pancreatic Cancer to the Cytotoxic Effects of Ionizing Radiation. Int J Radiat Oncol Biol Phys 2008, 71(3):873-879.
• [11]Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G, Hallahan DE: SU11248 Maintenance Therapy Prevents Tumor Regrowth after Fractionated Irradiation of Murine Tumor Models. Cancer Res 2003, 63(14):4009-4016.
• [12]Tanaka T, Munshi A, Brooks C, Liu J, Hobbs ML, Meyn RE: Gefitinib Radiosensitizes Non–Small Cell Lung Cancer Cells by Suppressing Cellular DNA Repair Capacity. Clin Cancer Res 2008, 14(4):1266-1273.
• [13]Williams KJ, Telfer BA, Shannon AM, Babur M, Stratford IJ, Wedge SR: Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTINTM; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts. Br J Radiol 2008, 81(Special Issue 1):S21-S27.
• [14]Bernier J, Bentzen SM, Vermorken JB: Molecular therapy in head and neck oncology. Nat Rev Clin Oncol 2009, 6(5):266-277.
• [15]Sun S, Schiller JH, Spinola M, Minna JD: New molecularly targeted therapies for lung cancer. J Clin Invest 2007, 117(10):2740-2750.
• [16]Shaw RJ, Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441(7092):424-430.
• [17]De Velasco MA, Uehura H: Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway. Advances in Urology 2012, 2012:1-12.
• [18]Rodriguez-Berriguete G, Fraile B, Martinez-Onsurbe P, Olmedilla G, Paniagua R, Royeula M: MAP Kinases and Prostate Cancer. Journal of Signal Transduction 2012, 2012:1-9.
• [19]Valerie K, Yacoub A, Hagan MP, Curiel DT, Fisher PB, Grant S, Dent P: Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther 2007, 6(3):789-801.
• [20]Jeggo PA, Lobrich M: DNA double-strand breaks: their cellular and clinical impact? Oncogene 2007, 26(56):7717-7719.
• [21]Kato TA, Okayasu R, Bedford JS: Comparison of the induction and disappearance of DNA double strand breaks and γ-H2AX foci after irradiation of chromosomes in G1-phase or in condensed metaphase cells. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 2008, 639(1–2):108-112.
• [22]Murata R, Nishimura Y, Hiraoka M: An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int J Radiat Oncol Biol Phys 1997, 37(5):1107-1113.
• [23]Williams KJ, Telfer BA, Brave S, Kendrew J, Whittaker L, Stratford IJ, Wedge SR: ZD6474, a Potent Inhibitor of Vascular Endothelial Growth Factor Signaling, Combined With Radiotherapy. Clin Cancer Res 2004, 10(24):8587-8593.
• [24]Zips D, Krause M, Hessel F, Westphal J, Bruchner K, Eicheler W, Dorfler A, Grenman R, Petersen C, Haberey M, et al.: Experimental Study on Different Combination Schedules of VEGF-receptor Inhibitor PTK787/ZK222584 and Fractionated Irradiation. Anticancer Res 2003, 23:3869-3876.
• [25]Zips D, Hessel F, Krause M, Schiefer Y, Hoinkis C, Thames HD, Haberey M, Baumann M: Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. Int J Radiat Oncol Biol Phys 2005, 61(3):908-914.
• [26]Zips D, Eicheler W, Geyer P, Hessel F, Dörfler A, Thames HD, Haberey M, Baumann M: Enhanced Susceptibility of Irradiated Tumor Vessels to Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibition. Cancer Res 2005, 65(12):5374-5379.
• [27]Hoang T, Huang S, Armstrong E, Eickhoff JC, Harari PM: Enhancement of radiation response with bevacizumab. J Exp Clin Cancer Res 2012., 31(37) [Epub ahead]